A Blood Test That Screens for 50+ Cancers Just Moved Closer to Real-World Use. Here's What It Means for Grail Investors. Lee Samaha, The Motley Fool Sun, June 21, 2026 at 3:25 PM PDT 5 min read Multi-cancer early detection (MCED) test company Grail (NASDAQ: GRAL) is one of the most fascinating mid-cap healthcare stocks on the market. Usually, when a company misses a primary endpoint in a landmark trial, it's time to fold the hand and focus on the next one. The reality is that many investors did just that, and the stock is down more than 30% in 2026 as I write. Still, there's a case building for its MCED test to receive approval from the Food and Drug Administration (FDA) and coverage from medical insurers. Here's what you need to know before investing in the stock. Grail's Galleri test The Galleri MCED test is intended to detect more than 50 cancers at an early stage, and in doing so, improve patient outcomes while significantly reducing treatment costs -- late-stage cancers (III and IV) are far more costly and invasive to treat. To demonstrate Galleri's efficacy, Grail conducted two high-profile studies: a 35,900-person study in North America (PATHFINDER 2) and a three-year, 142,000-person trial in England (NHS-Galleri) with England's National Health Service (NHS). Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue Unfortunately, Grail had bad news for investors in February when it released top-line results from the NHS and outlined that it had missed its primary endpoint of demonstrating "statistically significant Stage III-IV reduction" in its trial. The idea is that, by detecting cancer at early stages (I-II), the tested group should see a reduction in Stage III-IV cancers compared to the control group. The stock was, understandably, sold off heavily after the news broke, but has recovered about 18.4% as some investors are pricing in the possibility that Galleri could still receive FDA approval and coverage. Management sought to strengthen that case with a much-anticipated presentation at the American Society of Clinical Oncology (ASCO) annual meeting, only to receive a mixed reception from the market afterward. Where next for Grail and Galleri Despite missing a primary endpoint, management continues its iterative process with the FDA to secure approval for Galleri and provide more evidence of its suitability for medical coverage. There are potentially three factors that could favor the company achieving both. Image source: Getty Images. First, Grail believes 12-month follow-up data from the NHS trial will prove out the trial because "there are people in the control arm who have cancer that isn't being found because it hasn't presented clinically. So after another 12 months go by, more of those cancers will show up," according to CFO Aaron Freidin at a recent Goldman Sachs conference. Story Continues If the...
🔥 EXCLUSIVE PARTNER OFFER
500ML Capacity Fragrance Diffuser Smart Scent Air Machine For Home Professional Waterless Essential Oil Diffuser Air Freshener
🔥 Limited time offer! Grab your favorite item at an incredible price. Quality guaranteed!
Affiliate link — Commission earned at no extra cost to you
© EcoNews DZ — Global Economic & Financial News
.png)
Comments
Post a Comment